Insulet (PODD) Competitors $268.32 +2.93 (+1.10%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$268.33 +0.01 (+0.01%) As of 03/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PODD vs. BDX, EW, IDXX, RMD, DXCM, STE, BAX, HOLX, GMED, and MASIShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry. Insulet vs. Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed DexCom STERIS Baxter International Hologic Globus Medical Masimo Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership. Does the media prefer BDX or PODD? In the previous week, Becton, Dickinson and Company and Becton, Dickinson and Company both had 34 articles in the media. Becton, Dickinson and Company's average media sentiment score of 1.29 beat Insulet's score of 0.87 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 25 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 16 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community believe in BDX or PODD? Insulet received 134 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 66.40% of users gave Insulet an outperform vote while only 62.41% of users gave Becton, Dickinson and Company an outperform vote. CompanyUnderperformOutperformBecton, Dickinson and CompanyOutperform Votes60162.41% Underperform Votes36237.59% InsuletOutperform Votes73566.40% Underperform Votes37233.60% Which has more risk & volatility, BDX or PODD? Becton, Dickinson and Company has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Which has higher earnings and valuation, BDX or PODD? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBecton, Dickinson and Company$20.64B3.21$1.71B$6.0238.31Insulet$2.07B9.10$206.30M$5.7946.34 Do insiders & institutionals have more ownership in BDX or PODD? 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.5% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is BDX or PODD more profitable? Insulet has a net margin of 20.19% compared to Becton, Dickinson and Company's net margin of 8.47%. Insulet's return on equity of 24.46% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Becton, Dickinson and Company8.47% 15.74% 7.29% Insulet 20.19%24.46%8.33% Do analysts rate BDX or PODD? Becton, Dickinson and Company presently has a consensus price target of $278.29, indicating a potential upside of 20.66%. Insulet has a consensus price target of $292.06, indicating a potential upside of 8.85%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Becton, Dickinson and Company 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Insulet 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.82 SummaryInsulet beats Becton, Dickinson and Company on 10 of the 17 factors compared between the two stocks. Remove Ads Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.84B$4.44B$5.70B$8.12BDividend YieldN/A29.37%4.41%4.08%P/E Ratio46.3429.0824.1518.94Price / Sales9.1050.58394.5890.47Price / Cash75.9651.0838.1634.64Price / Book25.586.237.104.43Net Income$206.30M$67.64M$3.19B$247.05M7 Day Performance5.04%9.59%1.91%1.96%1 Month Performance-5.12%-2.97%3.55%-6.07%1 Year Performance63.30%22.51%14.43%3.77% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet3.9643 of 5 stars$268.32+1.1%$292.06+8.8%+61.0%$18.84B$2.07B46.343,000BDXBecton, Dickinson and Company4.8317 of 5 stars$227.84+0.8%$278.29+22.1%-4.5%$65.42B$20.64B37.8574,000Insider TradePositive NewsEWEdwards Lifesciences4.8222 of 5 stars$70.67+2.0%$79.95+13.1%-25.6%$41.55B$5.44B10.1417,300Positive NewsIDXXIDEXX Laboratories4.2999 of 5 stars$422.36+1.7%$533.75+26.4%-20.9%$34.35B$3.90B39.5810,800News CoveragePositive NewsRMDResMed4.7693 of 5 stars$224.46+0.1%$243.82+8.6%+13.4%$32.97B$4.93B26.508,160Analyst ForecastPositive NewsDXCMDexCom4.8788 of 5 stars$71.35+0.9%$99.82+39.9%-44.7%$27.88B$4.03B49.907,600STESTERIS4.5107 of 5 stars$227.84+0.5%$258.75+13.6%-3.0%$22.39B$5.40B48.3718,179News CoveragePositive NewsBAXBaxter International4.1552 of 5 stars$34.85+0.7%$38.56+10.6%-20.9%$17.83B$10.64B-27.2260,000Short Interest ↑HOLXHologic4.9397 of 5 stars$61.82+1.8%$84.62+36.9%-18.6%$13.87B$4.04B19.507,063Analyst RevisionNews CoveragePositive NewsGMEDGlobus Medical4.8178 of 5 stars$72.16+1.6%$97.82+35.5%+41.3%$9.93B$2.52B96.225,000Analyst ForecastMASIMasimo3.7621 of 5 stars$172.78+2.7%$194.80+12.7%+24.6%$9.32B$2.09B119.166,200Analyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives IDEXX Laboratories Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Baxter International Alternatives Hologic Alternatives Globus Medical Alternatives Masimo Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 3/22/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.